<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04985032</url>
  </required_header>
  <id_info>
    <org_study_id>RPCR-breast 01</org_study_id>
    <nct_id>NCT04985032</nct_id>
  </id_info>
  <brief_title>Accelerated Partial Breast Irradiation (APBI) Using Stereotactic Body Radiation Therapy (SBRT)</brief_title>
  <official_title>Accelerated Partial Breast Irradiation (APBI) Using Stereotactic Body Radiation Therapy (SBRT): a Multicenter, Observational Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GenesisCare USA</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GenesisCare USA</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The recently updated National Comprehensive Cancer Network (NCCN) Guidelines for Invasive&#xD;
      Breast Cancer (Version 1.2021) includes Accelerated Partial Breast Irradiation (APBI)&#xD;
      delivered by external beam methods in its Principles of Radiation Therapy section.&#xD;
&#xD;
      Studies of APBI suggest that rates of local control in selected low-risk patients with&#xD;
      early-stage breast cancer may be comparable to those treated with standard Whole Breast&#xD;
      Irradiation. Utilizing real-time image guidance, noncoplanar fields and respiratory tracking,&#xD;
      SBRT should allow for less normal tissue in the Planning Target Volume (PTV). potentially&#xD;
      reducing radiation-induced secondary tumors, toxicity to the lung, breast, heart, and&#xD;
      unacceptable cosmesis.&#xD;
&#xD;
      The primary endpoint of this registry study will be assessment of breast cosmesis and&#xD;
      toxicity following SBRT. Secondary endpoints will include assessment of ipsilateral breast&#xD;
      recurrences and overall survival. Our goal is to accrue at least 200 patients to the study.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      STUDY OBJECTIVES SBRT for treatment of the surgical cavity following partial mastectomy for&#xD;
      women with early-stage breast cancer will be studied. Target motion assessment and&#xD;
      correction, non-coplanar beam arrangement and stereotactic dose delivery will be required.&#xD;
      Ipsilateral breast cosmesis, dose to adjacent organs at risk, and acute and late toxicities&#xD;
      of treatment will be assessed.&#xD;
&#xD;
      ENDPOINTS The primary endpoints of this study are the assessments of acute and late&#xD;
      toxicities and breast cosmesis following SBRT. Secondary endpoints will include ipsilateral&#xD;
      breast recurrences and overall survival.&#xD;
&#xD;
      ELIGIBILITY Inclusion Criteria&#xD;
&#xD;
        1. Women 50 years or older&#xD;
&#xD;
        2. Low to intermediate grade DCIS or invasive ductal carcinoma&#xD;
&#xD;
        3. Tumor size &lt; 2 cm invasive ductal carcinoma and &lt; 2.5 cm DCIS&#xD;
&#xD;
        4. Well defined lumpectomy cavity on CT&#xD;
&#xD;
        5. Clear surgical ink margins &gt; 2mm for invasive cancer and &gt; 3 mm for DCIS&#xD;
&#xD;
        6. Node negative&#xD;
&#xD;
        7. Unifocal lesion&#xD;
&#xD;
        8. ER and/or PR positive&#xD;
&#xD;
        9. HER-2 negative&#xD;
&#xD;
       10. BRCA negative&#xD;
&#xD;
       11. Lumpectomy cavity must be &lt; 30% of whole breast volume&#xD;
&#xD;
      Exclusion Criteria&#xD;
&#xD;
        1. Lobular histology&#xD;
&#xD;
        2. Angiolymphatic invasion&#xD;
&#xD;
        3. Multiple foci of disease&#xD;
&#xD;
        4. Lymphovascular invasion&#xD;
&#xD;
        5. Active lupus or sarcoid&#xD;
&#xD;
        6. Distant metastases&#xD;
&#xD;
        7. Non-epithelial malignancies&#xD;
&#xD;
        8. Synchronous contralateral breast cancer&#xD;
&#xD;
        9. Grade 2 or higher oncoplastic surgery&#xD;
&#xD;
       10. Ipsilateral pacemaker&#xD;
&#xD;
       11. Ipsilateral breast implant&#xD;
&#xD;
       12. Neoadjuvant chemotherapy&#xD;
&#xD;
       13. Prior ipsilateral breast cancer or thoracic radiation&#xD;
&#xD;
       14. Poor breast integrity&#xD;
&#xD;
       15. Paget's Disease of the nipple&#xD;
&#xD;
       16. Pregnant patients&#xD;
&#xD;
       17. Severe cardiac, pulmonary, or liver diseases&#xD;
&#xD;
      RADIATION TREATMENT GUIDELINES and DOSIMETRY Fiducial Placement Prior to enrollment, patients&#xD;
      will undergo breast conservation surgery preferably with fiducial markers implanted at the&#xD;
      time of surgery or under ultrasonic guidance25&#xD;
&#xD;
        1. Patients treated with gantry-based SBRT preferably will have fiducials placed at the&#xD;
           time of surgery.&#xD;
&#xD;
        2. For patients being treated with CyberKnife SBRT, four gold markers will be placed&#xD;
           intraoperatively or ultrasonically to define the superior, inferior, medial, and lateral&#xD;
           boundaries of the lumpectomy cavity in accordance with the manufacturer's (Accuray)&#xD;
           documentation. At least three fiducials will be required for target tracking purposes to&#xD;
           allow for rotational changes.&#xD;
&#xD;
      Simulation Linear Accelerator SBRT For treatments on a gantry-based linear accelerator,&#xD;
      patients will be positioned supine with the arms elevated. CT scans will be obtained with&#xD;
      1.25 mm thickness and will be acquired with free breathing as well as additional scans as&#xD;
      needed for motion control or gating. 4DCT, MRI and PET imaging may be used to assist in&#xD;
      determining motion estimation.&#xD;
&#xD;
      CyberKnife SBRT For treatment on a robotic system, a contrast enhanced CT simulation is to be&#xD;
      performed with 1 mm slices with the patient's arms at her sides in the supine position. The&#xD;
      scan is to be performed with end-inspiratory breath hold from the thyroid to below the lungs.&#xD;
      Breast immobilization devices including a vacuum mattress and a bra system will be allowed&#xD;
      however bolus should not be used. Fiducial tracking (Synchrony) is to be used for motion&#xD;
      tracking.&#xD;
&#xD;
      DOSIMETRY Target and Organs at Risk (OAR) contours&#xD;
&#xD;
      The following structures are to be contoured in all patients:&#xD;
&#xD;
        -  Tumor cavity (GTV) as defined on CT including all fiducials implanted on CT images&#xD;
&#xD;
        -  Clinical Target Volume (CTV) defined as the tumor cavity expanded by a uniform 15 mm&#xD;
           margin. The CTV will not extend beyond the skin, breast or chestwall&#xD;
&#xD;
        -  Planning Tumor Volume (PTV) for SBRT will be defined as the CTV plus 3 - 5 mm as needed&#xD;
           at the treating physician's discretion. PTV will be limited to GTV plus 20 mm margin&#xD;
&#xD;
        -  Skin is defined as &lt;5 mm inside the external contour&#xD;
&#xD;
        -  Chest wall includes the ribs and intercoastal musculature but does not include the&#xD;
           pectoralis&#xD;
&#xD;
        -  Heart contour begins below the level of where the pulmonary trunk branches into the left&#xD;
           and right pulmonary arteries&#xD;
&#xD;
        -  Lungs are to be contoured separately&#xD;
&#xD;
        -  Spinal canal&#xD;
&#xD;
        -  Breasts are to be contoured separately&#xD;
&#xD;
      Dose Prescription The total prescribed dose to the PTV is 30 Gy delivered in 5 equal&#xD;
      fractions of 6 Gy per day delivered on alternating days over 5 -10 total days. The prescribed&#xD;
      dose must cover at least 95% of the PTV.&#xD;
&#xD;
      OAR Constraints&#xD;
&#xD;
        -  PTV- 100% &gt; 28.5 Gy (95% of the prescribed dose); Max dose to 0.03 cc &lt;105% of the&#xD;
           prescribed dose; &lt; 105% to &lt;15% of PTV&#xD;
&#xD;
        -  Ipsilateral whole breast - &lt; 50% will receive &lt; 15 Gy; Limit breast volume to &lt; 1000 cc.&#xD;
           The Lumpectomy cavity must be &lt; 30% of whole breast volume&#xD;
&#xD;
        -  Contralateral breast - &lt;3% of the prescribed dose to any point&#xD;
&#xD;
        -  Ipsilateral lung - &lt; 10% to receive 10 Gy&#xD;
&#xD;
        -  Contralateral lung - &lt; 5% to receive 5 Gy&#xD;
&#xD;
        -  Heart - &lt; 10% receives &gt; 3 Gy&#xD;
&#xD;
        -  Skin - 0.03 cc receives no more than 36 Gy&#xD;
&#xD;
        -  Chest Wall - 0.03 cc receives no more than 36 Gy&#xD;
&#xD;
        -  OAR within 5% of the listed constraints will be acceptable&#xD;
&#xD;
      Target Tracking Optical Surface Monitoring Systems, cone-beam CT, electromagnetic&#xD;
      transponders, on-board MRI, or fiducial motion tracking using kV imaging must be available to&#xD;
      monitor respiratory motion during treatment.&#xD;
&#xD;
      PATIENT ASSESSMENT Follow up visits will be done at 4-6 weeks, 6 months, 12 months, 18&#xD;
      months, 24 months and then yearly to 5 years. Patient's will have a history and physical,&#xD;
      yearly mammogram. Other investigations will only be done based upon suspicious symptoms or&#xD;
      signs. Treatment toxicity will be based on CTCAE version 4.0 and cosmesis based on global&#xD;
      cosmetic score (GCS) by the NRG-RTOG by both patient and physician. The GCS is a 4-point&#xD;
      scale: 1-Excellent, 2-Good, 3-Fair, 4-Poor. Digital photos of both breasts and closeup of the&#xD;
      treated breast will be taken at baseline and that each follow up and visit and will be rated&#xD;
      using the Harvard Cosmesis Scale (HCS). The HCS is also a 4-point scale that compares&#xD;
      symmetry, color and scar comparing the treated and untreated breast.&#xD;
&#xD;
      DATA MANAGEMENT Patient data will be collected by a designated staff member at each treating&#xD;
      facility and entered in the Registry for Performance and Clinical Outcomes in Radiosurgery in&#xD;
      the breast SBRT subsection. RPCR, Inc. (radiosurgery-registry.com) is a not-for-profit,&#xD;
      501c-6 organization, partnered with Doorn Corporation to handle the registry's data&#xD;
      collection and analytics. Doorn will provide management, support and maintenance of the&#xD;
      registry for all participating sites accessing the registry. The RPCR's database offers&#xD;
      multi-level data encryption, HIPAA compliance and is SSAE 18 certified.&#xD;
&#xD;
      IRB APPROVAL All participating sites will be required to obtain IRB approval prior to&#xD;
      enrollment of any patients. If no local IRB is available, a group IRB approved protocol can&#xD;
      be joined. IRB-approve patient consent will be obtained by the treating physician.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 2021</start_date>
  <completion_date type="Anticipated">December 2026</completion_date>
  <primary_completion_date type="Anticipated">December 2023</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Only</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>5 Years</target_duration>
  <primary_outcome>
    <measure>breast cosmesis</measure>
    <time_frame>2-3 years</time_frame>
    <description>physician and patient assessment of breast cosmetic result following SBRT</description>
  </primary_outcome>
  <primary_outcome>
    <measure>acute breast toxicity</measure>
    <time_frame>1-6 weeks</time_frame>
    <description>assessment of skin and breast tissue changes during and immediately following SBRT</description>
  </primary_outcome>
  <primary_outcome>
    <measure>other late toxicities</measure>
    <time_frame>3-60 months</time_frame>
    <description>assessment of pulmonary, cardiac and chest wall changes following SBRT</description>
  </primary_outcome>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Acute and Late Toxicities and Breast Cosmesis</condition>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>stereotactic body radiation therapy</intervention_name>
    <description>Treatment technique used to deliver a highly focused and accurate radiation dose to a defined target volume outside the brain; the entire course of therapy delivered in five fractions or less</description>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        SBRT for treatment of the surgical cavity following partial mastectomy for women with&#xD;
        early-stage breast cancer will be studied.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Women 50 years or older&#xD;
&#xD;
          2. Low to intermediate grade DCIS or invasive ductal carcinoma&#xD;
&#xD;
          3. Tumor size &lt; 2 cm invasive ductal carcinoma and &lt; 2.5 cm DCIS&#xD;
&#xD;
          4. Well defined lumpectomy cavity on CT&#xD;
&#xD;
          5. Clear surgical ink margins &gt; 2mm for invasive cancer and &gt; 3 mm for DCIS&#xD;
&#xD;
          6. Node negative&#xD;
&#xD;
          7. Unifocal lesion&#xD;
&#xD;
          8. ER and/or PR positive&#xD;
&#xD;
          9. HER-2 negative&#xD;
&#xD;
         10. BRCA negative&#xD;
&#xD;
         11. Lumpectomy cavity must be &lt; 30% of whole breast volume&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Lobular histology&#xD;
&#xD;
          2. Angiolymphatic invasion&#xD;
&#xD;
          3. Multiple foci of disease&#xD;
&#xD;
          4. Lymphovascular invasion&#xD;
&#xD;
          5. Active lupus or sarcoid&#xD;
&#xD;
          6. Distant metastases&#xD;
&#xD;
          7. Non-epithelial malignancies&#xD;
&#xD;
          8. Synchronous contralateral breast cancer&#xD;
&#xD;
          9. Grade 2 or higher oncoplastic surgery&#xD;
&#xD;
         10. Ipsilateral pacemaker&#xD;
&#xD;
         11. Ipsilateral breast implant&#xD;
&#xD;
         12. Neoadjuvant chemotherapy&#xD;
&#xD;
         13. Prior ipsilateral breast cancer or thoracic radiation&#xD;
&#xD;
         14. Poor breast integrity&#xD;
&#xD;
         15. Paget's Disease of the nipple&#xD;
&#xD;
         16. Pregnant patients&#xD;
&#xD;
         17. Severe cardiac, pulmonary, or liver diseases&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>50 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Mark Perman, MD</last_name>
    <phone>772-293-0377</phone>
    <email>Mark.Perman@usa.genesiscare.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Debra Freeman, MD</last_name>
    <phone>239-262-5168</phone>
    <email>tbck.md@gmail.com</email>
  </overall_contact_backup>
  <reference>
    <citation>National Comprehensive Cancer Network. Invasive Breast Cancer (Version 1.2021) https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf</citation>
  </reference>
  <reference>
    <citation>2Bonfantini F, De Martin E, Giandini T, Fumagalli ML, Cavallo A, Pinzi V, et al. A Dosimetric Comparison between Three Different External Photon Beam Techniques for Accelerated Partial Breast Irradiation. Clin Oncol. 2018; 3:1501.</citation>
  </reference>
  <reference>
    <citation>Hepel JT, Tokita M, MacAusland SG, Evans SB, Hiatt JR, Price LL, DiPetrillo T, Wazer DE. Toxicity of three-dimensional conformal radiotherapy for accelerated partial breast irradiation. Int J Radiat Oncol Biol Phys. 2009 Dec 1;75(5):1290-6. doi: 10.1016/j.ijrobp.2009.01.009. Epub 2009 Apr 22.</citation>
    <PMID>19395195</PMID>
  </reference>
  <reference>
    <citation>Wolmark N, Curran WJ, Vicini F, White J, Costantino JP, Arthur D, Kuske R, Rabinovitch R, Julian TB, Parda DS. Response to &quot;Unacceptable cosmesis in a protocol investigating intensity-modulated radiotherapy with active breathing control for accelerated partial-breast irradiation&quot; (Int J Radiat Oncol Biol Phys 2010;76:71-78) and &quot;Toxicity of three-dimensional conformal radiotherapy for accelerated partial breast irradiation&quot; Int J Radiat Oncol Biol Phys 2009;75:1290-1296). Int J Radiat Oncol Biol Phys. 2010 May 1;77(1):317; author reply 318. doi: 10.1016/j.ijrobp.2009.12.033.</citation>
    <PMID>20394863</PMID>
  </reference>
  <reference>
    <citation>Whelan TJ, Julian JA, Berrang TS, Kim DH, Germain I, Nichol AM, Akra M, Lavertu S, Germain F, Fyles A, Trotter T, Perera FE, Balkwill S, Chafe S, McGowan T, Muanza T, Beckham WA, Chua BH, Gu CS, Levine MN, Olivotto IA; RAPID Trial Investigators. External beam accelerated partial breast irradiation versus whole breast irradiation after breast conserving surgery in women with ductal carcinoma in situ and node-negative breast cancer (RAPID): a randomised controlled trial. Lancet. 2019 Dec 14;394(10215):2165-2172. doi: 10.1016/S0140-6736(19)32515-2. Epub 2019 Dec 5.</citation>
    <PMID>31813635</PMID>
  </reference>
  <reference>
    <citation>Vicini FA, Cecchini RS, White JR, Arthur DW, Julian TB, Rabinovitch RA, Kuske RR, Ganz PA, Parda DS, Scheier MF, Winter KA, Paik S, Kuerer HM, Vallow LA, Pierce LJ, Mamounas EP, McCormick B, Costantino JP, Bear HD, Germain I, Gustafson G, Grossheim L, Petersen IA, Hudes RS, Curran WJ Jr, Bryant JL, Wolmark N. Long-term primary results of accelerated partial breast irradiation after breast-conserving surgery for early-stage breast cancer: a randomised, phase 3, equivalence trial. Lancet. 2019 Dec 14;394(10215):2155-2164. doi: 10.1016/S0140-6736(19)32514-0. Epub 2019 Dec 5.</citation>
    <PMID>31813636</PMID>
  </reference>
  <reference>
    <citation>7White J. Cosmetic Outcomes from Post Lumpectomy Whole Breast Irradiation (WBI) Versus Partial Breast Irradiation (PBI) on the NRG Oncology/NSABP B39-RTOG 0413 Phase III Clinical Trial. ASTRO Annual Meeting. November 10, 2019.</citation>
  </reference>
  <reference>
    <citation>Coles CE, Griffin CL, Kirby AM, Titley J, Agrawal RK, Alhasso A, Bhattacharya IS, Brunt AM, Ciurlionis L, Chan C, Donovan EM, Emson MA, Harnett AN, Haviland JS, Hopwood P, Jefford ML, Kaggwa R, Sawyer EJ, Syndikus I, Tsang YM, Wheatley DA, Wilcox M, Yarnold JR, Bliss JM; IMPORT Trialists. Partial-breast radiotherapy after breast conservation surgery for patients with early breast cancer (UK IMPORT LOW trial): 5-year results from a multicentre, randomised, controlled, phase 3, non-inferiority trial. Lancet. 2017 Sep 9;390(10099):1048-1060. doi: 10.1016/S0140-6736(17)31145-5. Epub 2017 Aug 2.</citation>
    <PMID>28779963</PMID>
  </reference>
  <reference>
    <citation>Meattini I, Marrazzo L, Saieva C, Desideri I, Scotti V, Simontacchi G, Bonomo P, Greto D, Mangoni M, Scoccianti S, Lucidi S, Paoletti L, Fambrini M, Bernini M, Sanchez L, Orzalesi L, Nori J, Bianchi S, Pallotta S, Livi L. Accelerated Partial-Breast Irradiation Compared With Whole-Breast Irradiation for Early Breast Cancer: Long-Term Results of the Randomized Phase III APBI-IMRT-Florence Trial. J Clin Oncol. 2020 Dec 10;38(35):4175-4183. doi: 10.1200/JCO.20.00650. Epub 2020 Aug 24.</citation>
    <PMID>32840419</PMID>
  </reference>
  <reference>
    <citation>Hoekstra N, Habraken S, Swaak-Kragten A, Breedveld S, Pignol JP, Hoogeman M. Reducing the Risk of Secondary Lung Cancer in Treatment Planning of Accelerated Partial Breast Irradiation. Front Oncol. 2020 Aug 18;10:1445. doi: 10.3389/fonc.2020.01445. eCollection 2020.</citation>
    <PMID>33014782</PMID>
  </reference>
  <reference>
    <citation>Rahimi A, Thomas K, Spangler A, Rao R, Leitch M, Wooldridge R, Rivers A, Seiler S, Albuquerque K, Stevenson S, Goudreau S, Garwood D, Haley B, Euhus D, Heinzerling J, Ding C, Gao A, Ahn C, Timmerman R. Preliminary Results of a Phase 1 Dose-Escalation Trial for Early-Stage Breast Cancer Using 5-Fraction Stereotactic Body Radiation Therapy for Partial-Breast Irradiation. Int J Radiat Oncol Biol Phys. 2017 May 1;98(1):196-205.e2. doi: 10.1016/j.ijrobp.2017.01.020. Epub 2017 Jan 12.</citation>
    <PMID>28586960</PMID>
  </reference>
  <reference>
    <citation>Rahimi A, Morgan HE, Kim DW, Zhang Y, Leitch M, Wooldridge R, Goudreau S, Haley B, Rao R, Rivers A, Spangler AE, Jones RT, Stevenson S, Staley J, Albuquerque K, Ahn C, Neufeld S, Alluri PG, Ding C, Garwood D, Seiler S, Zhao B, Gu X, Timmerman R. Cosmetic Outcomes of a Phase 1 Dose Escalation Study of 5-Fraction Stereotactic Partial Breast Irradiation for Early Stage Breast Cancer. Int J Radiat Oncol Biol Phys. 2021 Jul 1;110(3):772-782. doi: 10.1016/j.ijrobp.2021.01.015. Epub 2021 Jan 18.</citation>
    <PMID>33476737</PMID>
  </reference>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>July 26, 2021</study_first_submitted>
  <study_first_submitted_qc>July 26, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 2, 2021</study_first_posted>
  <last_update_submitted>July 26, 2021</last_update_submitted>
  <last_update_submitted_qc>July 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

